(VSTM) Verastem, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VSTM) Verastem, Inc. Complete Analysis Pack
Explore the Complete Growth Strategy Behind the Preview
This Verastem, Inc. Ansoff Matrix Analysis helps you quickly assess the company’s growth options across market penetration, market development, product development, and diversification in one concise framework; this page includes a real preview/sample of the analysis so you can review style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific report for strategy, investment, or planning.
Market Penetration
RAMP 201 recurrent low-grade serous ovarian cancer
RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study in recurrent low-grade serous ovarian cancer, testing VS-6766 alone and with defactinib. This supports Verastem, Inc. market penetration by deepening its focus in a defined ovarian cancer niche already served by its pipeline.
The study design can expand clinical evidence in a rare disease segment where patient counts are limited, which matters for adoption and future label support.
VS-6766 and defactinib regimen
Defactinib is an oral FAK inhibitor, and pairing it with VS-6766 stacks RAF/MEK plus FAK blockade in one regimen. That widens Verastem, Inc.'s share of the same oncology space by deepening differentiation, not just broadening labels. In RAMP-201, the combo showed a 44% objective response rate in low-grade serous ovarian cancer, a clear proof point for market penetration.
RAMP 202 mutation-defined NSCLC
Verastem, Inc.'s RAMP 202 Phase 2 study targets a sharp late-line NSCLC niche: patients with KRAS or BRAF mutations after platinum therapy and immune checkpoint inhibitors. NSCLC is about 85% of lung cancers, while KRAS mutations appear in roughly 25% of NSCLC and BRAF in about 2%, so the pool is small but clearly defined. That makes this a focused market penetration move, not a broad launch.
RAMP 203 with Amgen LUMAKRAS
RAMP 203 is a Phase 1/2 study of Verastem, Inc.'s VS-6766 with Amgen's LUMAKRAS, so it pushes the same lead asset into a new KRAS-G12C combo setting. This is market penetration in Ansoff terms: Verastem is deepening use cases in precision oncology instead of moving to a new drug class.
- Phase 1/2 combo trial
- Extends precision-oncology reach
- Builds on VS-6766 data
- Targets KRAS-G12C biology
Chugai VS-6766 commercialization rights
Verastem has licensed development, manufacturing, and commercialization rights for VS-6766-based products to Chugai Pharmaceutical in Japan, giving the lead program a built-in route to market in a major pharma market. That setup widens future reach without Verastem funding a full local launch team.
- Chugai handles in-market execution.
- Verastem keeps pipeline reach via licensing.
- Japan rights support future penetration.
Verastem Deepens Oncology Reach with Strong RAMP 201 Signal
Verastem, Inc. is using market penetration by pushing VS-6766 and defactinib deeper into rare oncology niches, especially recurrent low-grade serous ovarian cancer and KRAS/BRAF-driven NSCLC. RAMP 201 posted a 44% objective response rate, which supports stronger use in the same disease pool.
RAMP 202 and RAMP 203 extend the same precision-oncology base into defined late-line and KRAS-G12C settings, while Chugai’s Japan rights add a second route to adoption.
| Program | Signal |
|---|---|
| RAMP 201 | 44% ORR |
| RAMP 202 | KRAS/BRAF NSCLC |
| RAMP 203 | KRAS-G12C combo |
What is included in the product
Detailed Word Document
Maps Verastem, Inc.’s growth options across existing and new products and markets through the Ansoff Matrix
Editable Excel File
Provides a quick, clear Ansoff Matrix view for Verastem, Inc. to simplify growth planning and strategic decision-making.
Reference Sources
Provides a concise, traceable bibliography of primary and reputable sources to validate Verastem growth-path assumptions for Ansoff Matrix analysis.
Market Development
Multicenter trial footprint
Verastem, Inc. uses multicenter trials to place the same asset in many oncology sites at once, widening investigator and patient access without changing the drug program. Its lead effort, avutometinib plus defactinib, moved through a global network of sites in 2025, which speeds enrollment and makes the same protocol visible to more centers. That is a direct market-development move: more sites, more reach, same core asset.
Ovarian cancer niche expansion
VS-6766 is being tested in recurrent low-grade serous ovarian cancer, a rare subgroup that makes up about 6% of ovarian cancers. Verastem, Inc. is moving from a broad ovarian cancer theme into a narrower market with an existing asset, which fits market development in the Ansoff Matrix. With more than 20,000 U.S. ovarian cancer cases each year, even a small niche can still support meaningful revenue.
Biomarker-defined lung cancer entry
Verastem, Inc.'s RAMP 202 targets KRAS- and BRAF-mutant NSCLC, a biomarker-defined slice of lung cancer that sits inside the ~85% of cases that are non-small cell. KRAS mutations appear in about 25% of NSCLC, while BRAF mutations are near 2%, so the same platform can enter a distinct, mutation-led market. This is market development: one therapy class, new tumor segment, and a sharper path to label expansion.
Later-line NSCLC setting
The NSCLC study enrolls patients after platinum-based regimens and immune checkpoint inhibitors, so Verastem, Inc. is moving the same asset into a later-line setting. That widens use across a new point in care, where post-progression options are still limited and treatment decisions shift to disease control and tolerability.
- Later-line NSCLC market
- Post-platinum, post-ICI patients
- Same asset, new use case
Partner commercialization channel
Verastem, Inc.'s Chugai deal gives Chugai commercialization and manufacturing rights, so VS-6766 can reach partner-led markets without Verastem building local sales or supply lines. That is a low-capex way to widen access to the same asset and keep capital focused on core programs.
This matters more after the May 2025 U.S. approval of avutometinib plus defactinib for recurrent KRAS-mutant low-grade serous ovarian cancer, which gives the franchise a real commercial base to export through partners. The model can scale faster than direct entry when a market needs local labeling, reimbursement, and manufacturing support.
In Ansoff terms, it is market development: same product, new geography, partner-led execution. One approved product can now serve more than one route to market.
- Chugai handles local commercialization
- Chugai also handles manufacturing rights
- VS-6766 expands beyond direct reach
- Uses the same product in new markets
Verastem Expands Its Oncology Franchise Into New Markets
Verastem, Inc. is using the same oncology assets in new diseases, lines of therapy, and geographies, which is classic market development. In 2025, avutometinib plus defactinib won U.S. approval for recurrent KRAS-mutant low-grade serous ovarian cancer, giving the franchise a live base to expand from.
RAMP 202 also pushes the platform into post-platinum, post-ICI KRAS/BRAF-mutant NSCLC, while Chugai gives local commercialization and manufacturing reach without a full U.S.-only buildout.
| Move | 2025 data |
|---|---|
| Approval | 1 U.S. label |
| Ovarian niche | ~6% of cases |
| NSCLC base | ~85% of lung cancers |
Get Your Copy
Verastem, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
Dual RAF MEK clamp mechanism
VS-6766 is Verastem, Inc.'s core innovation: a dual RAF/MEK inhibitor that uses a clamp mechanism to block MEK kinase activity and RAF-driven MEK phosphorylation. That 2-target design gives the company a clear product-development edge inside the Ansoff Matrix, since it deepens the current pipeline with a differentiated molecule. It is the main value driver in Verastem's current oncology strategy.
VS-6766 monotherapy arm
RAMP 201 tests VS-6766 as a single agent in a Phase 1/2 setting, so Verastem, Inc. can measure standalone activity without the noise of a partner drug. That fits Ansoff product development: it refines the same oncology asset inside the same market. The monotherapy arm also helps define response, dose, and tolerability before broader use.
VS-6766 and defactinib combination product
Verastem, Inc. is advancing VS-6766 with defactinib, a focal adhesion kinase inhibitor, as a new regimen for existing cancer markets. In RAMP-201, the combo produced a 44% objective response rate in recurrent low-grade serous ovarian cancer, supporting a product-development move with clear clinical use.
The addressable market is still meaningful: about 6,000 to 8,000 U.S. women live with this rare ovarian cancer subtype, and many need better options after platinum therapy. That makes the pair a practical line extension in oncology, not a new market bet.
VS-6766 and LUMAKRAS combination
RAMP 203 tests VS-6766 plus LUMAKRAS in KRAS-G12C tumors, creating a new combo around the same mutation target. It adds a second program to Verastem, Inc.'s combo-led pipeline, building on LUMAKRAS, the first FDA-approved KRAS G12C inhibitor in 2021. The pairing aims to deepen pathway blockade and widen clinical use.
- KRAS-G12C focused pairing
- Combo-led pipeline expansion
- Built on LUMAKRAS approval
Pfizer FAK inhibitor rights
Verastem’s Pfizer FAK inhibitor rights give it access to a second kinase class, so it can build new oncology products around the FAK pathway instead of starting from zero. FAK, or focal adhesion kinase, is a validated cancer target, and the license helps Verastem reuse Pfizer’s existing chemistry and know-how to cut early R&D risk. In Ansoff terms, this is product development: new drugs for the same cancer market.
- Second inhibitor class access
- Lower early discovery risk
- Supports FAK-based pipeline growth
Verastem’s Pipeline Expands With Strong Combo Trial Momentum
Verastem, Inc.’s product development centers on VS-6766, a dual RAF/MEK inhibitor, and the company’s combo trials deepen the same oncology market instead of entering a new one. In RAMP 201, VS-6766 plus defactinib posted a 44% objective response rate in recurrent low-grade serous ovarian cancer.
RAMP 203 extends the pipeline into KRAS-G12C tumors with LUMAKRAS, widening use of the same pathway logic. Pfizer FAK rights also give Verastem, Inc. a second kinase platform to build on.
| Program | Signal |
|---|---|
| VS-6766 | Core asset |
| RAMP 201 | 44% ORR |
| RAMP 203 | KRAS-G12C combo |
Diversification
FAK inhibitor use cases
Verastem, Inc.’s FAK inhibitor diversification is broader because the Pfizer agreement spans 3 use cases: therapeutic, diagnostic, and prophylactic. That moves the asset beyond a single treatment format and can support more than 1 market path. In Ansoff terms, it widens both product scope and market reach for the collaboration.
KRAS-G12C combination program
RAMP 203 pairs Verastem, Inc.'s VS-6766 with Amgen's LUMAKRAS, moving Verastem into the KRAS-G12C precision oncology space. This adds a second combo path beyond its lead MEK/RAF program and broadens its Ansoff diversification. KRAS-G12C occurs in about 13% of NSCLC and 3% to 4% of colorectal cancer.
Partner-led pipeline expansion
Verastem’s partner-led pipeline uses 3 active collaborators, Chugai, Pfizer, and Amgen, so development risk is split across multiple external programs. That matters for diversification: one deal can fail without sinking the whole pipeline, and each partner opens a separate path to licensing, milestones, or supply. The model widens Verastem’s product sources and market reach while limiting single-asset dependence.
Ovarian and lung cancer portfolio
Verastem, Inc. is spreading risk across two oncology bets: recurrent low-grade serous ovarian cancer, about 5% of ovarian cancers, and NSCLC, which makes up about 80% to 85% of lung cancers. That mix lowers dependence on one disease area and widens the commercial base.
The portfolio has different clinical and payer paths, so one program can still add value if the other slows. In Ansoff terms, this is product diversification inside oncology, not a single-market push.
- Two separate cancer markets
- Lower single-disease exposure
- Broader pipeline optionality
Commercialization and manufacturing network
Verastem, Inc. gains diversification through the Chugai license because it covers development, commercialization, and manufacturing rights, so the Company is not tied to internal execution alone. That widens operational reach and lowers single-point risk across the VS-6766 asset chain.
The move can extend market access beyond a single launch path, which matters as VS-6766 advances into broader oncology use. In Ansoff terms, this is a stronger route to product-market expansion with shared control over supply and go-to-market execution.
- License spans development, commercialization, manufacturing
- Adds reach beyond internal execution
- Supports wider VS-6766 market footprint
Verastem Spreads Risk Across Partners and Expands Its Oncology Reach
Verastem, Inc. uses diversification by spreading oncology risk across 3 partners: Chugai, Pfizer, and Amgen. VS-6766 now covers recurrent low-grade serous ovarian cancer, about 5% of ovarian cancers, plus KRAS-G12C tumors in about 13% of NSCLC and 3% to 4% of colorectal cancer.
That widens product scope, market reach, and deal optionality beyond a single asset.
| Driver | Data | Ansoff read |
|---|---|---|
| Partners | 3 | Risk spread |
| LGSC share | ~5% | Disease focus |
| KRAS-G12C | 13% NSCLC; 3%-4% CRC | Market expansion |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.